Clinical Trial Detail

NCT ID NCT02720185
Title The Window of Opportunity of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Recruitment Suspended
Gender female
Phase Phase II
Variant Requirements No
Sponsors University of Wisconsin, Madison
Indications

triple-receptor negative breast cancer

Therapies

Dasatinib

Age Groups: adult

No variant requirements are available.